Cardiovascular events were defined as a composite of all-cause death, myocardial infarction, or stroke through 12 months and occurred in 5.5% of patients assigned to the GnRH antagonist compared with 4.1% in in those assigned to GnRH antagonist (HR: 1.28; 95% CI: 0.59-2.79; P = 0.53). The gene discussed is GNRH1; the disease is stroke disorder.